---
title: "Novo Nordisk Advances Amycretin to Phase 3 Trials for Weight Management Treatment"
description: "Novo Nordisk A/S has advanced its investigational treatment, amycretin, into phase 3 trials for weight management. This follows findings published in The Lancet and presentations at the ADA 85th Scien"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/245515170.md"
published_at: "2025-06-20T23:34:59.000Z"
---

# Novo Nordisk Advances Amycretin to Phase 3 Trials for Weight Management Treatment

> Novo Nordisk A/S has advanced its investigational treatment, amycretin, into phase 3 trials for weight management. This follows findings published in The Lancet and presentations at the ADA 85th Scientific Sessions. The trials evaluated the safety and weight loss potential of amycretin, which combines GLP-1 and amylin receptor agonism. Results showed it was tolerable with a safety profile similar to other treatments. The phase 3 trials will further assess its therapeutic potential for weight management.

Novo Nordisk A/S has announced the advancement of its investigational treatment, amycretin, into phase 3 trials for weight management. This decision follows the publication of findings in The Lancet and presentations at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US. The clinical trials evaluated the safety, tolerability, and weight loss potential of both subcutaneous and oral forms of amycretin in individuals with overweight or obesity. The results indicated that amycretin was tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists. Amycretin is noted as the first treatment to combine GLP-1 and amylin receptor agonism in a single molecule, offering complementary effects on appetite control. The phase 3 trials aim to further assess its potential as a therapeutic option for weight management. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001103993-en) on June 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? | As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? | [Link](https://longbridge.com/en/news/270794581.md) |
| Novo's Wegovy pill approved in the US as the first oral GLP-1 treatment; JPY outperformer following further jawboning - Newsquawk EU Market Open | Novo Nordisk's Wegovy pill has been approved in the US as the first oral GLP-1 treatment for weight management. Meanwhil | [Link](https://longbridge.com/en/news/270580763.md) |
| Advance Auto Parts’ Heavy Debt Load Raises Liquidity, Refinancing and Turnaround Risks | Advance Auto Parts Inc (AAP) is facing significant financial risks due to its heavy debt load, which may limit liquidity | [Link](https://longbridge.com/en/news/275997122.md) |
| Melco Resorts & Entertainment (MLCO) Is Down 12.9% After Return To Quarterly Profitability And Record Five-Star Awards | Melco Resorts & Entertainment reported a Q4 2025 revenue of $1.29 billion, swinging to a $60.64 million profit from a pr | [Link](https://longbridge.com/en/news/276002958.md) |
| Wall Street bullish on AtaiBeckley (ATAI), here’s why | Wall Street is optimistic about AtaiBeckley Inc. (NASDAQ:ATAI), identifying it as a top penny stock with a potential ups | [Link](https://longbridge.com/en/news/276000823.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.